The research paper explores the multifaceted role of the IL-17 family in immune response, covering everything from infection control to pathological conditions like autoimmune diseases and cancer. Future therapies may exploit IL-17’s unique signaling pathways to offer more targeted and cost-effective treatments.
IDH Inhibitor Activity in Brain Cancer Persists With Longer Follow-Up
HOUSTON — Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to